Search

Displaying results 831 - 840 of 2815 in total
  1. Drug

    Sucralfate

    go.drugbank.com/drugs/DB00364
    ApprovedInvestigational

    It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076].

    Products: SUCRALFATO MYLAN GENERICS, SUCRALFATO DOC GENERICI
  2. Drug

    Lifileucel

    go.drugbank.com/drugs/DB17107
    ApprovedInvestigational

    Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient which undergo isolation, ex vivo expansion, and activation Lifileucel was granted accelerated approval by ...

  3. Drug

    Albumin human

    go.drugbank.com/drugs/DB00062
    ApprovedInvestigational

    Also known as _Albuminex_ 5% or 25%, one brand of human serum albumin is prepared from the pooled plasma of US donors in FDA-licensed facilities in the US [F229].

  4. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    [L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being [miglitol]), receiving its first FDA approval in 1995 under the brand name Precose (since discontinued

    Products: ACARBOSIO DOC GENERICI
  5. Drug

    Buspirone

    go.drugbank.com/drugs/DB00490
    ApprovedInvestigational

    [A180985] First synthesized in 1968 then patented in 1975,[L7375] it is commonly marketed under the brand name Buspar®.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  6. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    [L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 Inhibitors
  7. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    [A261165] On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    PF-06260414

    go.drugbank.com/drugs/DB15221
    Investigational

    PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

  9. Drug

    Queuine

    go.drugbank.com/drugs/DB14732
    ExperimentalNutraceutical

    Humans salvage and recover queuine from either ingested food or the gut flora.

  10. Drug

    PF-06282999

    go.drugbank.com/drugs/DB11683
    Investigational

    Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).